Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination

Bibliography

• International Diabetes Federation. Guideline for management of postmeal glucose in diabetes. International Diabetes Federation; Brussels, Belgium: 2011
   Google Scholar
• Inoue M. Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2012;13:2257-68
   PubMed Web of Science ®Google Scholar
• Ono Y, Kameda H, Cho KY. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2013;14:361-70
   PubMed Web of Science ®Google Scholar
• Tatsumi F, Hashiramoto M, Hirukawa H, et al. Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus. Diabetes Res Clin Pract 2013; [ Epub ahead of print]
   PubMedGoogle Scholar
• Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2012;14:1040-6
   PubMed Web of Science ®Google Scholar
• Nonaka K, Tsubouchi H, Okuyama K, et al. Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res 2009;41:232-7
   PubMed Web of Science ®Google Scholar
• Rauch T, Graefe-Mody U, Deacon CF, et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther 2012;3:10
   PubMedGoogle Scholar
• Inagaki N, Watada H, Murai M, et al. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2013;15:833-43
   PubMed Web of Science ®Google Scholar
• Tajima N, Kadowaki T, Okamoto T, et al. Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes. J Diabetes Investig 2013;4:595-604
   PubMed Web of Science ®Google Scholar
• Kaku K, Inagaki N, Kobayashi N. Long-term effects of mitiglinide in Japanese diabetics inadequately controlled with DPP-4 inhibitor or biguanide monotherapy. Diabetes Ther 2014;5(1):97-111
   PubMedGoogle Scholar
• Jung JA, Kaku K, Kim JH, et al. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus. Adv Ther 2013;30:1018-29
   PubMedGoogle Scholar
• Kudo-Fujimaki K, Hirose T, Yoshihara T, et al. Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide. J Diabetes Investig 2013; [Epub ahead of print]
   PubMedGoogle Scholar
• Kaku K, Tanaka K, Origasa H, et al. [Concomitant effects of a rapid and short acting insulin secretagogue mitiglinide in type 2 diabetes patients with inadequate control of blood glucose with voglibose monotherapy - Phase II/III double blind comparative study]. Jpn Pharmacol Ther 2007;35:S51-72
   Google Scholar
• Malaisse WJ. Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Expert Opin Pharmacother 2008;9:2691-8
   PubMed Web of Science ®Google Scholar
• Phillippe HM, Wargo KA. Mitiglinide for type 2 diabetes treatment. Expert Opin Pharmacother 2013;14:2133-44
   PubMed Web of Science ®Google Scholar
• Kaku K. Efficacy of voglibose in type 2 diabetes. Expert Opin Pharmacother 2014;15:1181-91
   PubMed Web of Science ®Google Scholar
• Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-14
   PubMed Web of Science ®Google Scholar
• Ono Y, Nakamura A, Cho KY, et al. The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2014;15:311-24
   PubMed Web of Science ®Google Scholar
• Ohta A, Ohshige T, Sakai K, et al. Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naive Japanese patients with type 2 diabetes. Expert Opin Pharmacother 2013;14:2315-22
   PubMed Web of Science ®Google Scholar
• Ando K, Nishimura R, Tsujino D, et al. 24-hour glycemic variations in drug-naive patients with type 2 diabetes: a continuous glucose monitoring (CGM)-based study. PLoS One 2013;8:e71102
   PubMedGoogle Scholar
• Tsujino D, Nishimura R, Taki K, et al. Comparing the efficacy of alpha-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study. Diabetes Technol Ther 2011;13:303-8
   PubMed Web of Science ®Google Scholar
• Yoshino G, Tominaga M, Hirano T, et al. The test meal A: a pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. J Jpn Diabetes Soc 2006;49:361-71
   Google Scholar
• Seo C, Sakamoto M, Nishimura R, et al. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study. Diabetes Technol Ther 2013;15:378-85
   PubMed Web of Science ®Google Scholar
• Stingl H, Krssak M, Krebs M, et al. Lipid-dependent control of hepatic glycogen stores in healthy humans. Diabetologia 2001;44:48-54
   PubMedGoogle Scholar
• Bajaj M, Pratipanawatr T, Berria R, et al. Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes. Diabetes 2002;51:3043-8
   PubMedGoogle Scholar
• Jovanovic A, Gerrard J, Taylor R. The second-meal phenomenon in type 2 diabetes. Diabetes Care 2009;32:1199-201
   PubMedGoogle Scholar
• Schmidt MI, Lin QX, Gwynne JT, Jacobs S. Fasting early morning rise in peripheral insulin: evidence of the dawn phenomenon in nondiabetes. Diabetes Care 1984;7:32-5
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C, Dejager S, Owens D. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care 2013;36:4057-62
   PubMedGoogle Scholar
• Aoki K, Kamiyama H, Yoshimura K, et al. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. Acta Diabetol 2012;49:225-30
   PubMed Web of Science ®Google Scholar